Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HER2-newC apoptosis inducer
- Development stage
- Preclinical
- Lead developer
- IcanoMAB
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous, Intramuscular, Oral, Topical, Intranasal, Transdermal, Intrathecal
01
Overview
HER2-newC apoptosis inducer is a monoclonal antibody currently in the IND-enabling stage of development by IcanoMAB GmbH, in partnership with MAB Discovery GmbH. It specifically targets the Human Epidermal Growth Factor Receptor 2 (HER2) and is designed for the treatment of HER2-positive breast cancer, including early-stage disease. Unlike traditional HER2-targeted therapies that primarily inhibit signaling or recruit immune cells, this candidate is characterized by its ability to directly induce apoptosis in HER2-expressing cancer cells. The antibody was originally generated using MAB Discovery's proprietary antibody discovery platform and is part of IcanoMAB's portfolio of precision canonical antibodies.
- Other names
- HER2-newC apoptosis inducerHER-2-newC apoptosis inducerHER 2-newC apoptosis inducer
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on HER2-newC apoptosis inducer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HER2-newC apoptosis inducer.